OS Therapies Inc. Files S-1 Registration Statement

TL;DR

OS Therapies just filed an S-1, looks like they're gearing up for an IPO.

AI Summary

OS Therapies Inc. filed an S-1 registration statement on May 30, 2024, indicating plans to offer securities. The company, incorporated in Delaware with its principal executive offices in Rockville, Maryland, operates in the pharmaceutical preparations sector (SIC 2834). Paul A. Romness serves as the President and Chief Executive Officer.

Why It Matters

This S-1 filing signals OS Therapies Inc.'s intention to raise capital through a public offering, which could fund its pharmaceutical development and expansion efforts.

Risk Assessment

Risk Level: medium — As an S-1 filing, it indicates a company is preparing to go public, which inherently carries risks associated with market volatility and the success of its business model.

Key Numbers

• 333-279839 — SEC File Number (Identifies the specific SEC registration)
• 241006494 — Film Number (Internal SEC processing number)

Key Players & Entities

• OS Therapies Inc. (company) — Registrant
• May 30, 2024 (date) — Filing Date
• Delaware (jurisdiction) — State of Incorporation
• Rockville, Maryland (location) — Principal Executive Offices
• 2834 (industry_code) — Primary SIC Code (Pharmaceutical Preparations)
• Paul A. Romness (person) — President and Chief Executive Officer

FAQ

Key Financial Figures

• $4.00 — ssumed initial public offering price is $4.00 per share. We have applied to list our

Filing Documents

• ea0205761-03.htm (S-1) — 5551KB
• ea020576103ex1-1_osthera.htm (EX-1.1) — 244KB
• ea020576103ex3-1_osthera.htm (EX-3.1) — 55KB
• ea020576103ex3-2_osthera.htm (EX-3.2) — 11KB
• ea020576103ex3-3_osthera.htm (EX-3.3) — 123KB
• ea020576103ex4-1_osthera.htm (EX-4.1) — 8KB
• ea020576103ex4-2_osthera.htm (EX-4.2) — 75KB
• ea020576103ex4-3_osthera.htm (EX-4.3) — 101KB
• ea020576103ex4-4_osthera.htm (EX-4.4) — 97KB
• ea020576103ex4-5_osthera.htm (EX-4.5) — 99KB
• ea020576103ex5-1_osthera.htm (EX-5.1) — 11KB
• ea020576103ex10-1_osthera.htm (EX-10.1) — 34KB
• ea020576103ex10-2_osthera.htm (EX-10.2) — 116KB
• ea020576103ex10-3_osthera.htm (EX-10.3) — 112KB
• ea020576103ex10-4_osthera.htm (EX-10.4) — 115KB
• ea020576103ex10-5_osthera.htm (EX-10.5) — 236KB
• ea020576103ex10-5i_osthera.htm (EX-10.5(I)) — 17KB
• ea020576103ex10-6_osthera.htm (EX-10.6) — 157KB
• ea020576103ex10-7_osthera.htm (EX-10.7) — 38KB
• ea020576103ex10-8_osthera.htm (EX-10.8) — 41KB
• ea020576103ex10-10_osthera.htm (EX-10.10) — 82KB
• ea020576103ex10-11_osthera.htm (EX-10.11) — 125KB
• ea020576103ex10-11i_osthera.htm (EX-10.11(I)) — 7KB
• ea020576103ex10-12_osthera.htm (EX-10.12) — 31KB
• ea020576103ex23-1_osthera.htm (EX-23.1) — 3KB
• ea020576103ex-fee_osthera.htm (EX-FILING FEES) — 37KB
• tos_logo.jpg (GRAPHIC) — 83KB
• timage_001.jpg (GRAPHIC) — 324KB
• timage_002.jpg (GRAPHIC) — 333KB
• tflowchart_001.jpg (GRAPHIC) — 317KB
• ex5-1_001.jpg (GRAPHIC) — 15KB
• ex5-1_002.jpg (GRAPHIC) — 10KB
• ex10-7_001.jpg (GRAPHIC) — 4KB
• ex10-8_001.jpg (GRAPHIC) — 5KB
• ex10-12_001.jpg (GRAPHIC) — 2KB
• ex23-1_001.jpg (GRAPHIC) — 21KB
• ex23-1_002.jpg (GRAPHIC) — 66KB
• 0001213900-24-048049.txt ( ) — 9153KB

RISK FACTORS

RISK FACTORS   14 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS   50

USE OF PROCEEDS

USE OF PROCEEDS   51 DIVIDEND POLICY   53 CAPITALIZATION   54

DILUTION

DILUTION   55 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   57

BUSINESS

BUSINESS   69 MANAGEMENT   87

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION   94

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   98 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS   99

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK   101 SHARES ELIGIBLE FOR FUTURE SALE   106

UNDERWRITING

UNDERWRITING   108 LEGAL MATTERS   112 EXPERTS   112 WHERE YOU CAN FIND MORE INFORMATION   112 INDEX TO FINANCIAL STATEMENTS   F-1 i Table of Contents ABOUT THIS PROSPECTUS We have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any applicable prospectus supplement. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate only as of the date on the front of those documents only, regardless of the time of delivery of this prospectus or any applicable prospectus supplement, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not, and the underwriters are not, offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted. We and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities as to distribution of the prospectus outside of the United States. The industry and market data and certain other statistical information used throughout this prospectus are f

View Full Filing

View this S-1 filing on SEC EDGAR